e-therapeutics plc (LON:ETX – Get Free Report)’s stock price fell 6.7% during mid-day trading on Thursday . The stock traded as low as GBX 9 ($0.11) and last traded at GBX 9 ($0.11). 2,518,125 shares changed hands during trading, an increase of 232% from the average session volume of 758,869 shares. The stock had previously closed at GBX 9.65 ($0.12).
e-therapeutics Stock Performance
The business has a 50-day simple moving average of GBX 11.18 and a 200 day simple moving average of GBX 11.74. The company has a debt-to-equity ratio of 0.33, a current ratio of 22.20 and a quick ratio of 20.13. The firm has a market cap of £52.59 million, a PE ratio of -450.00 and a beta of 0.48.
e-therapeutics Company Profile
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Read More
- Five stocks we like better than e-therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Roblox: The Bottom Just Fell Out of the Metaverse
- 3 Monster Growth Stocks to Buy Now
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- What is the Euro STOXX 50 Index?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
